These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18435429)

  • 1. Globally optimal trial design for local decision making.
    Eckermann S; Willan AR
    Health Econ; 2009 Feb; 18(2):203-16. PubMed ID: 18435429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expected value of information and decision making in HTA.
    Eckermann S; Willan AR
    Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accounting for between-study variation in incremental net benefit in value of information methodology.
    Willan AR; Eckermann S
    Health Econ; 2012 Oct; 21(10):1183-95. PubMed ID: 21882285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time and expected value of sample information wait for no patient.
    Eckermann S; Willan AR
    Value Health; 2008; 11(3):522-6. PubMed ID: 18179665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods.
    Chen MH; Willan AR
    Clin Trials; 2013 Feb; 10(1):54-62. PubMed ID: 23263520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of value of information: best informing research design and prioritization using current methods.
    Eckermann S; Karnon J; Willan AR
    Pharmacoeconomics; 2010; 28(9):699-709. PubMed ID: 20629473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal global value of information trials: better aligning manufacturer and decision maker interests and enabling feasible risk sharing.
    Eckermann S; Willan AR
    Pharmacoeconomics; 2013 May; 31(5):393-401. PubMed ID: 23529209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods.
    Willan A; Kowgier M
    Clin Trials; 2008; 5(4):289-300. PubMed ID: 18697843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal sample size determinations from an industry perspective based on the expected value of information.
    Willan AR
    Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revolution then evolution: the advance of health economic evaluation in Australia.
    Lopert R; Viney R
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):360-6. PubMed ID: 25444293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of research and value of development in early assessments of new medical technologies.
    Retèl VP; Grutters JP; van Harten WH; Joore MA
    Value Health; 2013; 16(5):720-8. PubMed ID: 23947964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of information analyses of economic randomized controlled trials: the treatment of intermittent claudication.
    Groot Koerkamp B; Spronk S; Stijnen T; Hunink MG
    Value Health; 2010; 13(2):242-50. PubMed ID: 19818058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of information analysis optimizing future trial design from a pilot study on catheter securement devices.
    Tuffaha HW; Reynolds H; Gordon LG; Rickard CM; Scuffham PA
    Clin Trials; 2014 Dec; 11(6):648-56. PubMed ID: 25084784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies.
    Sully BG; Julious SA; Nicholl J
    Trials; 2013 Jun; 14():166. PubMed ID: 23758961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the marginal value of 'better' research output: 'designed' versus 'routine' data in randomised controlled trials.
    Cohen D; Longo MF; Williams J; Cheung WY; Hutchings H; Russell IT
    Health Econ; 2003 Nov; 12(11):959-74. PubMed ID: 14601158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The option value of delay in health technology assessment.
    Eckermann S; Willan AR
    Med Decis Making; 2008; 28(3):300-5. PubMed ID: 18480035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prioritizing investments in health technology assessment. Can we assess potential value for money?
    Davies L; Drummond M; Papanikolaou P
    Int J Technol Assess Health Care; 2000; 16(1):73-91. PubMed ID: 10815355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion and use of health technology assessment in policy making: what lessons for decentralised healthcare systems?
    Ciani O; Tarricone R; Torbica A
    Health Policy; 2012 Dec; 108(2-3):194-202. PubMed ID: 23093020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health technology assessment in its local contexts: studies of telehealthcare.
    May C; Mort M; Williams T; Mair F; Gask L
    Soc Sci Med; 2003 Aug; 57(4):697-710. PubMed ID: 12821017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient design of cluster randomized and multicentre trials with unknown intraclass correlation.
    van Breukelen GJ; Candel MJ
    Stat Methods Med Res; 2015 Oct; 24(5):540-56. PubMed ID: 21937473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.